Sean Fielding appointed as Chair of influential university-business collaboration organisation, PraxisAuril
22 Jan 2019
Congratulations to Sean Fielding, Director of Innovation, Impact and Business at the University of Exeter who has been appointed as the new Chair of PraxisAuril until 2021.
10 Jan 2019
As a second generation of quantum devices begins to move out of physics labs and into the marketplace, Andrew Fearnside, Senior Associate at Appleyard Lees, offers a tour through the developing commercial landscape.
9 Jan 2019
Research England has today published a document detailing proposals for how the Knowledge Exchange Framework (KEF) could work and would like to hear the HE sector’s views on these proposals.
3 Jan 2019
The Transport Systems Catapult's (TSC) Academic Network for Intelligent Mobility (ANIM) is currently the primary method of communicating with TSC's academic stakeholders and researchers to tell them about our latest news events and opportunities. The network facilitates an environment for exchange of ideas, knowledge, learning and the opportunity to promote collaboration.
3 Jan 2019
Clinical trial launches to develop breath test for multiple cancers
13 Dec 2018
This Quarter's edition of Spinouts UK looks at the ways in which universities can make the most of their environment with spotlights on Swansea University and the Midlands MIRA initiative.
12 Dec 2018
We would like to take this opportunity to say thank you to all our members for their support over the past year. I hope you can take a moment to celebrate what we achieved with that support by reading on, and onto a short summary of our 2018 impact.
11 Dec 2018
The 145th European Study Group with Industry (ESGI) - 8-12 April 2019 - University of Cambridge
6 Dec 2018
PraxisAuril member the Institute for Cancer Research has released a report looking at cancer drug delivery in the NHS and the rate of drug development across different types of cancer. ‘Patent to Patient’ analysed the regulatory regime and found that NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use.